查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1748677

结缔组织疾病治疗市场（按疾病、药物、配销通路、国家和地区）—2024 年至 2032 年的行业分析、市场规模、市场份额和预测

Connective Tissue Disease Treatment Market, By Disease, By Drug, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 303 Pages | 商品交期: 2-3个工作天内

价格
简介目录

报告重点

2024 年结缔组织疾病治疗市场规模价值为 241.691 亿美元，2024 年至 2032 年的复合年增长率为 5.89%。

结缔组织疾病治疗市场-市场动态

自体免疫疾病盛行率上升

类风湿性关节炎、红斑性狼疮和硬皮症等自体免疫疾病的发生率不断上升，是结缔组织疾病治疗市场的主要驱动力。随着全球范围内越来越多的人被诊断出患有这些慢性疾病，对有效治疗方案的需求也持续增长。人口老化、认知度的提高以及诊断能力的提升有助于更早发现和开始治疗。患者数量的激增迫使製药公司投资于新型疗法的研发，包括生物製剂和标靶免疫抑制剂。因此，这一趋势正在推动市场成长，并扩大先进治疗方案的可用性。

结缔组织疾病治疗市场-关键见解

根据我们的研究分析师，全球结缔组织疾病治疗市场预计在 2024 年至 2032 年期间的复合年增长率约为 5.89%。

2023 年按疾病细分，类风湿性关节炎 (RA) 类别占据了市场主导地位。

根据药物，生物製药部门在 2023 年创造了最多的收入。

按地区划分，2023年北美是收入最高的地区。

结缔组织疾病治疗市场-細項分析：

全球结缔组织疾病治疗市场分为三类：疾病、药物、配销通路和地区。

结缔组织疾病治疗市场按疾病类型分为几个主要领域：类风湿性关节炎 (RA)、系统性红斑狼疮 (SLE)、硬皮症、多发性肌炎、皮肌炎、干燥症、混合性结缔组织疾病 (MCTD)、未分化结缔组织疾病 (UCTD) 和其他结缔组织疾病。每种疾病都需要针对性治疗，通常涉及免疫抑制剂、生物製剂和症状管理策略。其中，类风湿性关节炎 (RA) 因其高发病率及其对患者生活品质的重大影响而成为主要领域。 RA 驱动着大部分市场需求，生物疗法和改善病情的抗风湿药物 (DMARD) 的持续进步，提高了疗效并改善了患者预后。 RA 发病率的上升，加上治疗方案的不断创新，巩固了其在市场上的领先地位。

结缔组织疾病治疗市场按药物类型细分为药品和生物製药。药品主要包括传统药物，如非类固醇类抗发炎药物 (NSAID)、皮质类固醇和免疫抑制药物，用于控制发炎和控制症状。生物製药涵盖生物製剂，如单株抗体、标靶治疗和其他先进的生物疗法，旨在改变疾病进展和免疫系统反应。其中，生物製药因其在治疗复杂自体免疫疾病方面的卓越功效而占据市场主导地位。生物製剂的兴起，尤其是在类风湿性关节炎和狼疮等疾病中的兴起，彻底改变了治疗模式，为患者提供了更个人化和有效的治疗方案。在持续的研究、新药审批和更好的患者治疗效果的支持下，生物製药持续推动市场成长。

结缔组织疾病治疗市场-地理洞察

从地理分布来看，结缔组织疾病治疗市场分布于北美、亚太地区、拉丁美洲、欧洲、中东和非洲。这些区域根据业务来源国进一步划分。

北美是结缔组织疾病治疗市场的主导地区，这主要得益于类风湿性关节炎、红斑性狼疮和硬皮症等自体免疫疾病的高发性。美国凭藉其先进的医疗基础设施、早期诊断以及人口老化（这些疾病更容易引发这些疾病）占据了显着的市场份额。该地区也受益于大型製药和生物製药公司的存在，这些公司在新疗法的研发上投入了大量资金。此外，优惠的报销政策和人们对自体免疫疾病认识的提高也促进了市场的成长。对创新生物製剂和免疫抑制剂的需求进一步加速了该地区的主导地位，使其在市场规模和治疗进展方面都处于领先地位。

欧洲是结缔组织疾病治疗市场的另一个主导地区，这得益于其自体免疫疾病发病率的不断上升、完善的医疗保健体係以及先进疗法的广泛普及。德国、法国、英国和义大利等国家是该市场的主要贡献者，这些国家对类风湿性关节炎和狼疮等疾病的认识日益加深。欧盟审批新药的监管框架，加上支持性的公共医疗保健体系，促进了创新疗法的可用性和可近性。此外，欧洲是医学研究和生物製药创新的中心，许多公司专注于开发新的生物製剂和疗法。领先製药公司的强大影响力以及对自体免疫疾病研究不断增长的投资，进一步巩固了欧洲作为主要市场参与者的地位。

结缔组织疾病治疗市场-竞争格局：

结缔组织疾病治疗市场的竞争态势由老牌製药巨头和新兴生物製药公司共同塑造，这些公司均专注于创新并拓展产品组合。艾伯维、安进、勃林格殷格翰、百时美施贵宝和罗氏等主要公司凭藉种类繁多的生物製剂和免疫抑制剂占据市场主导地位，并大力投资研发以提高疗效和安全性。新进业者也透过标靶疗法和个人化医疗方法推动市场发展。这种竞争环境促进了持续创新，推动着为结缔组织疾病患者开发更有效、更方便的治疗方法。

最新动态：

2025年2月，艾伯维以2.5亿美元收购Celsius Therapeutics，加强了对自体免疫疾病的关注。 Celsius正在开发CEL383，这是一种针对与发炎性肠道疾病(IBD)相关的基因TREM1的口服抗体。此次收购补充了艾伯维多元化免疫学产品线的策略，尤其是在其从Humira转向Skyrizi和Rinvoq等较新的疗法之际。

2024年6月，辉瑞推出了一种旨在改善狼疮患者预后的新型生物疗法。这项进展彰显了辉瑞致力于满足自体免疫疾病领域未满足需求的承诺。该疗法是辉瑞增强其免疫学和自体免疫疾病治疗产品组合的更广泛策略的一部分。

目录

第一章：结缔组织疾病治疗市场概述

  • 研究范围
  • 市场估计年限

第二章：执行摘要

  • 市场片段
    • 结缔组织疾病治疗市场片段（依疾病）
    • 结缔组织疾病治疗市场（按药物）摘要
    • 结缔组织疾病治疗市场（按配销通路）
    • 结缔组织疾病治疗市场（按国家/地区）
    • 结缔组织疾病治疗市场（按地区）
  • 竞争洞察

第三章：结缔组织疾病治疗主要市场趋势

  • 结缔组织疾病治疗市场驱动因素
    • 市场驱动因素的影响分析
  • 结缔组织疾病治疗市场限制
    • 市场限制的影响分析
  • 结缔组织疾病治疗市场机会
  • 结缔组织疾病治疗市场未来趋势

第四章：结缔组织疾病治疗产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第五章：结缔组织疾病治疗市场：COVID-19 影响分析

  • COVID-19 之前的影响分析
  • 新冠疫情后影响分析
    • 表现最佳的市场区隔
    • 边际成长细分市场
    • 最鬆散的细分市场
    • 边际损失部分

第六章：结缔组织疾病治疗市场格局

  • 2023年结缔组织疾病治疗市占率分析
  • 按主要製造商分類的细分数据
    • 成熟玩家分析
    • 新兴企业分析

第七章：结缔组织疾病治疗市场 - 按疾病

  • 概述
    • 按疾病细分的份额分析
    • 类风湿性关节炎（RA）
    • 系统性红斑狼疮（SLE）
    • 硬皮症
    • 多发性肌炎
    • 皮肌炎
    • 干燥症
    • 混合结缔组织疾病（MCTD）
    • 未分化结缔组织疾病（UCTD）
    • 其他结缔组织疾病

第 8 章：结缔组织疾病治疗市场 - 按药物

  • 概述
    • 按药物细分的市占率分析
    • 製药
      • 非类固醇抗发炎药（NSAID）
      • 改善病情的抗风湿药物（DMARDs）
      • 皮质类固醇
      • 其他药品
    • 生物製药
      • 生物製剂
      • TNF抑制剂
      • IL-6抑制剂
      • B细胞抑制剂
      • T细胞抑制剂
      • 其他生物製剂
      • 生物相似药

第九章：结缔组织疾病治疗市场－按配销通路

  • 概述
    • 按配销通路分類的细分市场份额分析
    • 医院药房
    • 零售药局
    • 网路药局

第 10 章：结缔组织疾病治疗市场-按地域划分

  • 介绍
    • 按地区分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美结缔组织疾病治疗主要製造商
    • 北美市场规模及预测（按国家/地区）
    • 北美市场规模及预测（按疾病）
    • 北美市场规模及预测（按药品）
    • 北美市场规模及预测（按配销通路）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲结缔组织疾病治疗主要製造商
    • 欧洲市场规模及预测（按国家/地区）
    • 欧洲市场规模及预测（按疾病）
    • 欧洲市场规模及预测（按药品）
    • 欧洲市场规模及预测（按配销通路）
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 英国
    • 俄罗斯
    • 荷兰
    • 瑞典
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区结缔组织疾病治疗主要製造商
    • 亚太市场规模及预测（按国家/地区）
    • 亚太市场规模及预测（按疾病）
    • 亚太市场规模及预测（按药品）
    • 亚太市场规模及预测（按配销通路）
    • 印度
    • 中国
    • 韩国
    • 日本
    • 澳洲
    • 泰国
    • 印尼
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲
    • 概述
    • 拉丁美洲结缔组织疾病治疗主要製造商
    • 拉丁美洲市场规模及预测（按国家/地区）
    • 拉丁美洲市场规模及预测（按疾病）
    • 拉丁美洲市场规模及预测（按药品）
    • 拉丁美洲市场规模及预测（按配销通路）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲
    • 概述
    • 中东和非洲结缔组织疾病治疗主要製造商
    • 中东和非洲市场规模及预测（按国家/地区）
    • 中东和非洲市场规模及预测（按疾病）
    • 中东和非洲市场规模及预测（按药品）
    • 中东和非洲市场规模及预测（按配销通路）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 其余地区

第 11 章：关键供应商分析-结缔组织疾病治疗产业

  • 竞争仪錶板
  • 公司简介
    • AbbVie, Inc.
    • Amgen, Inc.
    • Boehringer Ingelheim International GmbH
    • Bristol-Myers Squibb Company
    • F. Hoffmann-La Roche Ltd.
    • Johnson & Johnson Services, Inc.
    • Lily
    • Novartis AG
    • Pfizer Inc.
    • Regeneron Pharmaceuticals Inc.
    • UCB SA
    • Others

第 12 章：360 度分析师视角

第 13 章：附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
简介目录
Product Code: ANV5227

REPORT HIGHLIGHT

Connective Tissue Disease Treatment Market size was valued at USD 24,169.10 Million in 2024, expanding at a CAGR of 5.89% from 2024 to 2032.

Connective tissue disease treatment involves managing autoimmune conditions that affect tissues like skin, joints, muscles, and organs. Treatment typically focuses on reducing inflammation, controlling immune system activity, and relieving symptoms. Common approaches include nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, immunosuppressants, and disease-modifying antirheumatic drugs (DMARDs). Biologic therapies may be used in severe cases. Physical therapy and lifestyle modifications support mobility and overall health. Treatment is tailored to the specific disease, such as lupus, scleroderma, or rheumatoid arthritis, and varies based on severity and organ involvement. Regular monitoring and multidisciplinary care are essential to prevent complications and improve long-term outcomes.

Connective Tissue Disease Treatment Market- Market Dynamics

Rising Prevalence of Autoimmune Disorders

The growing incidence of autoimmune diseases such as rheumatoid arthritis, lupus, and scleroderma is a major driver for the connective tissue disease treatment market. As more individuals are diagnosed with these chronic conditions globally, the demand for effective treatment options continues to rise. Aging populations, increased awareness, and improved diagnostic capabilities contribute to earlier detection and treatment initiation. This surge in patient populations compels pharmaceutical companies to invest in research and development of novel therapies, including biologics and targeted immunosuppressants. Consequently, this trend is fueling market growth and expanding the availability of advanced therapeutic solutions.

Connective Tissue Disease Treatment Market- Key Insights

According to our research analyst, the global Connective Tissue Disease Treatment Market is expected to develop at a CAGR of approximately 5.89% between 2024-2032.

Segmented by Disease in 2023, the Rheumatoid Arthritis (RA) category dominated the market.

Based on Drug, the Biopharmaceuticals segment generated the most income in 2023.

On the basis of region, in 2023, North America was the region with the highest revenue.

Connective Tissue Disease Treatment Market- Segmentation Analysis:

The global Connective Tissue Disease Treatment Market is divided into three categories: Disease, Drug, Distribution Channel and Region.

The connective tissue disease treatment market is categorized by disease type into several key segments: Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Scleroderma, Polymyositis, Dermatomyositis, Sjogren's Syndrome, Mixed Connective Tissue Disease (MCTD), Undifferentiated Connective Tissue Disease (UCTD), and other connective tissue diseases. Each condition requires a tailored treatment approach, often involving immunosuppressants, biologics, and symptom management strategies. Among these, Rheumatoid Arthritis (RA) is the dominant segment due to its high prevalence and the significant impact it has on patients' quality of life. RA drives the majority of market demand, with ongoing advancements in biologic therapies and disease-modifying antirheumatic drugs (DMARDs) that offer improved efficacy and patient outcomes. The rising incidence of RA, combined with continuous innovation in treatment options, solidifies its leading position in the market.

The connective tissue disease treatment market is segmented by drug type into Pharmaceuticals and Biopharmaceuticals. Pharmaceuticals primarily include traditional drugs like nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and immunosuppressive medications that help control inflammation and manage symptoms. Biopharmaceuticals encompass biologic agents such as monoclonal antibodies, targeted therapies, and other advanced biologic treatments that aim to modify the disease's progression and immune system response. Among these, Biopharmaceuticals dominate the market due to their superior efficacy in treating complex autoimmune conditions. The rise of biologics, particularly in diseases like rheumatoid arthritis and lupus, has revolutionized treatment paradigms, offering patients more personalized and effective therapies. Biopharmaceuticals continue to drive market growth, supported by ongoing research, new drug approvals, and better patient outcomes.

Connective Tissue Disease Treatment Market- Geographical Insights

Geographically, the Connective Tissue Disease Treatment Market is distributed throughout North America, Asia Pacific, Latin America, Europe, the Middle East, and Africa. These regions are further divided based on the nations bringing in business.

North America is the dominant region in the connective tissue disease treatment market, driven by the high prevalence of autoimmune diseases like rheumatoid arthritis, lupus, and scleroderma. The United States, in particular, holds a significant market share due to advanced healthcare infrastructure, early diagnosis, and an aging population, which is more susceptible to these diseases. The region also benefits from the presence of major pharmaceutical and biopharmaceutical companies, which invest heavily in research and development of new treatments. Additionally, favorable reimbursement policies and improved awareness around autoimmune disorders contribute to the market's growth. The demand for innovative biologics and immunosuppressants further accelerates the region's dominance, making it a leader in both market size and therapeutic advancements.

Europe is another dominant region in the connective tissue disease treatment market, owing to the increasing incidence of autoimmune diseases, robust healthcare systems, and widespread availability of advanced treatments. Countries like Germany, France, the United Kingdom, and Italy are key contributors to the market, with growing awareness about diseases such as rheumatoid arthritis and lupus. The European Union's regulatory framework for approving new drugs, combined with supportive public healthcare systems, promotes the availability and accessibility of innovative treatments. Additionally, Europe is a hub for medical research and biopharmaceutical innovation, with numerous companies focused on developing new biologics and therapies. The strong presence of leading pharmaceutical companies and growing investment in autoimmune disease research further solidify Europe's position as a major market player.

Connective Tissue Disease Treatment Market- Competitive Landscape:

The competitive dynamics of the Connective Tissue Disease Treatment Market are shaped by a blend of established pharmaceutical giants and emerging biopharmaceutical companies, all focused on innovation and expanding their product portfolios. Major players such as AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, and F. Hoffmann-La Roche dominate the market with a wide range of biologics and immunosuppressants, heavily investing in research and development to improve treatment efficacy and safety. New entrants are also advancing the market with targeted therapies and personalized medicine approaches. This competitive environment fosters continuous innovation, driving the development of more effective and accessible treatments for patients with connective tissue diseases.

Recent Developments:

In February 2025, AbbVie intensified its focus on autoimmune diseases by acquiring Celsius Therapeutics for $250 million. Celsius is developing CEL383, an oral antibody targeting TREM1, a gene associated with inflammatory bowel disease (IBD). This acquisition complements AbbVie's strategy to diversify its immunology pipeline, particularly as it shifts from Humira to newer therapies like Skyrizi and Rinvoq.

In June 2024, Pfizer launched a new biologic therapy aimed at improving outcomes for patients with lupus. This development underscores Pfizer's commitment to addressing unmet needs in autoimmune diseases. The therapy is part of Pfizer's broader strategy to enhance its portfolio in immunology and autoimmune disease treatments.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CONNECTIVE TISSUE DISEASE TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • AbbVie, Inc.
  • Amgen, Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson Services, Inc.
  • Lily
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • UCB S.A.
  • Others

GLOBAL CONNECTIVE TISSUE DISEASE TREATMENT MARKET, BY DISEASE - MARKET ANALYSIS, 2019 - 2032

  • Rheumatoid Arthritis (RA)
  • Systemic Lupus Erythematosus (SLE)
  • Scleroderma
  • Polymyositis
  • Dermatomyositis
  • Sjogren's Syndrome
  • Mixed Connective Tissue Disease (MCTD)
  • Undifferentiated Connective Tissue Disease (UCTD)
  • Other connective tissue diseases

GLOBAL CONNECTIVE TISSUE DISEASE TREATMENT MARKET, BY DRUG - MARKET ANALYSIS, 2019 - 2032

  • Pharmaceuticals
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
  • Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
  • Corticosteroids
  • Other Pharmaceuticals
  • Biopharmaceuticals
  • Biologics
  • TNF Inhibitors
  • IL-6 Inhibitors
  • B-cell Inhibitors
  • T-cell Inhibitors
  • Other Biologics
  • Biosimilars

GLOBAL CONNECTIVE TISSUE DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL INDUSTRY - MARKET ANALYSIS, 2019 - 2032

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

GLOBAL CONNECTIVE TISSUE DISEASE TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Connective Tissue Disease Treatment Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Connective Tissue Disease Treatment Market Snippet by Disease
    • 2.1.2. Connective Tissue Disease Treatment Market Snippet by Drug
    • 2.1.3. Connective Tissue Disease Treatment Market Snippet by Distribution Channel
    • 2.1.4. Connective Tissue Disease Treatment Market Snippet by Country
    • 2.1.5. Connective Tissue Disease Treatment Market Snippet by Region
  • 2.2. Competitive Insights

3. Connective Tissue Disease Treatment Key Market Trends

  • 3.1. Connective Tissue Disease Treatment Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Connective Tissue Disease Treatment Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Connective Tissue Disease Treatment Market Opportunities
  • 3.4. Connective Tissue Disease Treatment Market Future Trends

4. Connective Tissue Disease Treatment Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Connective Tissue Disease Treatment Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Connective Tissue Disease Treatment Market Landscape

  • 6.1. Connective Tissue Disease Treatment Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Connective Tissue Disease Treatment Market - By Disease

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Disease, 2023 & 2032 (%)
    • 7.1.2. Rheumatoid Arthritis (RA)
    • 7.1.3. Systemic Lupus Erythematosus (SLE)
    • 7.1.4. Scleroderma
    • 7.1.5. Polymyositis
    • 7.1.6. Dermatomyositis
    • 7.1.7. Sjogren's Syndrome
    • 7.1.8. Mixed Connective Tissue Disease (MCTD)
    • 7.1.9. Undifferentiated Connective Tissue Disease (UCTD)
    • 7.1.10. Other connective tissue diseases

8. Connective Tissue Disease Treatment Market - By Drug

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Drug, 2023 & 2032 (%)
    • 8.1.2. Pharmaceuticals
      • 8.1.2.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
      • 8.1.2.2. Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
      • 8.1.2.3. Corticosteroids
      • 8.1.2.4. Other Pharmaceuticals
    • 8.1.3. Biopharmaceuticals
      • 8.1.3.1. Biologics
      • 8.1.3.1.1. TNF Inhibitors
      • 8.1.3.1.2. IL-6 Inhibitors
      • 8.1.3.1.3. B-cell Inhibitors
      • 8.1.3.1.4. T-cell Inhibitors
      • 8.1.3.1.5. Other Biologics
      • 8.1.3.2. Biosimilars

9. Connective Tissue Disease Treatment Market - By Distribution Channel

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution Channel, 2023 & 2032 (%)
    • 9.1.2. Hospital Pharmacies
    • 9.1.3. Retail Pharmacies
    • 9.1.4. Online Pharmacies

10. Connective Tissue Disease Treatment Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Connective Tissue Disease Treatment Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Connective Tissue Disease Treatment Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.8. France
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. France Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.3.8.4. France Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.3.8.5. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.9. Italy
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. Italy Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.3.9.4. Italy Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.3.9.5. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.10. Spain
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. United Kingdom Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.3.10.4. United Kingdom Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.3.10.5. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.11. United Kingdom
      • 10.3.11.1. Overview
      • 10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.3. United Kingdom Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.3.11.4. United Kingdom Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.3.11.5. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.12. Russia
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2. Russia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.3.12.3. Russia Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.3.12.4. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.13. Netherlands
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2. Netherlands Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.3.13.3. Netherlands Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.14. Sweden
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2. Sweden Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.3.14.3. Sweden Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.15. Poland
      • 10.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.2. Poland Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.3.15.3. Poland Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.16. Rest of Europe
      • 10.3.16.1. Overview
      • 10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.16.3. Rest of the Europe Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.3.16.4. Rest of the Europe Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.3.16.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Connective Tissue Disease Treatment Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.9. South Korea
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. South Korea Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.4.9.4. South Korea Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.4.9.5. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.10. Japan
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. Japan Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.4.10.4. Japan Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.4.10.5. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Connective Tissue Disease Treatment Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Connective Tissue Disease Treatment Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Connective Tissue Disease Treatment Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. AbbVie, Inc.
    • 11.2.2. Amgen, Inc.
    • 11.2.3. Boehringer Ingelheim International GmbH
    • 11.2.4. Bristol-Myers Squibb Company
    • 11.2.5. F. Hoffmann-La Roche Ltd.
    • 11.2.6. Johnson & Johnson Services, Inc.
    • 11.2.7. Lily
    • 11.2.8. Novartis AG
    • 11.2.9. Pfizer Inc.
    • 11.2.10. Regeneron Pharmaceuticals Inc.
    • 11.2.11. UCB S.A.
    • 11.2.12. Others

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us